Company intelligence / Profile preview
Kangweizhonghe
Zhongshan, Guangdong Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Kangweizhonghe is advancing skin test products for tuberculosis, including the recombinant Mycobacterium tuberculosis antigen (D-EC), which is undergoing multicenter Phase II clinical trials in China exploring safety, tolerability, and dosing. The lead program's clinical results are not finalized—most trials are preclinical or early-phase.
- Therapeutic areas
- EndocrinologyInfectious DiseasesHematologyOncologyNeurology
- Modalities
- NanobodyProphylactic vaccineOther diagnostic agentFusion proteinTherapeutic vaccine
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Kangweizhonghe.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangweizhonghe.